- Home
- AMAL vs PHVS Comparison
AMAL vs PHVS Comparison
Compare AMAL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- PHVS
- Stock Information
- Founded
- AMAL 1923
- PHVS 2015
- Country
- AMAL United States
- PHVS Switzerland
- Employees
- AMAL N/A
- PHVS N/A
- Industry
- AMAL Commercial Banks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- PHVS Health Care
- Exchange
- AMAL Nasdaq
- PHVS Nasdaq
- Market Cap
- AMAL 858.7M
- PHVS 1.3B
- IPO Year
- AMAL 2018
- PHVS 2021
- Fundamental
- Price
- AMAL $27.81
- PHVS $24.32
- Analyst Decision
- AMAL Hold
- PHVS Strong Buy
- Analyst Count
- AMAL 2
- PHVS 5
- Target Price
- AMAL $33.00
- PHVS $35.60
- AVG Volume (30 Days)
- AMAL 149.9K
- PHVS 127.0K
- Earning Date
- AMAL 10-23-2025
- PHVS 11-12-2025
- Dividend Yield
- AMAL 1.99%
- PHVS N/A
- EPS Growth
- AMAL 3.73
- PHVS N/A
- EPS
- AMAL 3.34
- PHVS N/A
- Revenue
- AMAL $304,724,000.00
- PHVS N/A
- Revenue This Year
- AMAL $9.82
- PHVS N/A
- Revenue Next Year
- AMAL $11.11
- PHVS N/A
- P/E Ratio
- AMAL $8.44
- PHVS N/A
- Revenue Growth
- AMAL 4.35
- PHVS N/A
- 52 Week Low
- AMAL $25.03
- PHVS $11.51
- 52 Week High
- AMAL $38.19
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- AMAL 39.31
- PHVS 59.79
- Support Level
- AMAL $27.41
- PHVS $23.20
- Resistance Level
- AMAL $29.19
- PHVS $24.02
- Average True Range (ATR)
- AMAL 0.65
- PHVS 1.37
- MACD
- AMAL -0.07
- PHVS 0.05
- Stochastic Oscillator
- AMAL 16.06
- PHVS 85.39
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.